Moreover, clinical studies determined that treatment with conatumumab (an anti-DR5 agent) in breast cancer patients could be considered safe [54], and improved the survival rate in phase II studies of colorectal cancer patients [55]. The gene discussed is TNFRSF10B; the disease is colorectal cancer.